Timeline of incretin therapeutics (revision 3)
Old revision·18:53, 8 Aug 2024·TirzTaxonomist
This is an old revision of this page, as it stood at 18:53, 8 Aug 2024, saved by TirzTaxonomist with the summary reorder the analogues chronologically rather than alphabetically. It may differ substantially from the current revision, and any error it contains may since have been corrected.
| Timeline of incretin therapeutics | |
|---|---|
| Span | 1900s to the present |
| Arrangement | Chronological |
| List infobox · conventions | |
This timeline sets out the development of incretin science and of the drugs derived from it, from the earliest observation that oral glucose provokes a larger insulin response than intravenous glucose, to the multi-receptor agonists in development.[1]
Dates are given for the events most consistently reported in the literature. Where a discovery is attributable to a series of publications rather than one, the timeline names the period rather than a single year.[2]
Physiology
[edit]| Period | Event |
|---|---|
| 1900s–1920s | Observation that oral glucose evokes a larger insulin response than intravenous |
| 1960s | The term incretin revived; the enteroinsular axis proposed |
| 1970s | GIP isolated and characterised |
| 1980s | Glucagon-like peptide-1 identified as a proglucagon product and shown to be insulinotropic |
| 1986 | Reduced Incretin effect documented in type 2 diabetes |
| 1990s | Dipeptidyl peptidase-4 identified as the enzyme inactivating both incretins |
The 1986 finding is the hinge of the field: it established that the incretin axis is defective in type 2 diabetes and therefore a therapeutic target rather than only a physiological curiosity.[2]
References
Categories: